Eisai, Inc. is a multinational company headquartered in Tokyo and founded in 1941 with overseas branches, subsidiaries and factories throughout Europe, America and Asia.

This article summarized the latest R&D progress of Pralatrexate, the Mechanism of Action for Pralatrexate, and the drug target R&D trends for Pralatrexate.

The multinational healthcare firm, Viatris Inc., has shared news of the tentative approval from FDA)for an abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg oral suspension tablet New Drug Application .

The 5-HT1A receptor is one of the most widely distributed 5-HT receptors, present on the cell bodies and dendrites of 5-HT neurons, situated in the raphe nucleus and the terminal location of 5-HT release.

Swedish precision oncology firm, Beactica Therapeutics AB, has today unveiled BEA-17 as their chosen preclinical candidate within the LSD1 initiative

Daiichi Sankyo Co., Ltd. is a pharmaceutical organization based in Tokyo-to, Japan.

ACM Biolabs has revealed encouraging preliminary findings from a Phase I evaluation of ACM-001, their inaugural clinical-stage development initiative.

This article summarized the latest R&D progress of Pemafibrate, the Mechanism of Action for Pemafibrate, and the drug target R&D trends for Pemafibrate.

Is it sufficient to solely search for nucleotide sequences when searching for a specific nucleotide sequence? Certainly not.

InvIOs GmbH revealed today that it has launched patient enrollment for a Phase 1b trial of its innovative autologous cell therapy, APN401, focusing on solid tumor patients.

Hypercholesterolemia refers to a condition in which the cholesterol level in the blood is abnormally elevated.

Relay Therapeutics is a well-known drug discovery company in recent years, characterized by computational chemistry, with three drugs in its pipeline all from D.E. Shaw.